Bruce E. Hillner Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor–positive breast cancer Cancer 101
Version of Record online: 6 AUG 2004 | DOI: 10.1002/cncr.20492
The results of a computer simulation based on ATAC (‘Arimidex, Tamoxifen Alone or in Combination’) trial data suggest that in the adjuvant treatment of early-stage estrogen receptor–positive breast cancer, anastrozole will provide substantial long-term benefit in terms of disease-free survival (DFS). If this DFS benefit were to ultimately lead to a survival benefit, then anastrozole would have an acceptable incremental cost per life year gained for women with a life expectancy of > 12 years from the start of treatment.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field